Michael Rettig, PhD

Michael Rettig, PhD

Primary Academic Title

Associate Professor of Medicine, Division of Oncology, Section of Stem Cell Biology, Washington University School of Medicine

Research Interest

Developing strategies that will maximize the graft-versus-leukemia (GVL) effect while minimizing graft- versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation.


  • 2000: PhD, chemistry, Purdue University, West Lafayette, Ind.


  • 2000 - 2003: Postdoctoral fellow, oncology, Washington University, St. Louis

Selected Research Publications

An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies.
  • Xiang J, Devenport JM, Carter AJ, [...] Rettig MP, [...] DiPersio JF
  • Leukemia 2023
Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma.
  • Yao L, Wang JT, Jayasinghe RG, [...] Rettig MP, [...] DiPersio JF
  • Cancer Res 2023
The tetraspanin CD53 protects stressed hematopoietic stem cells via promotion of DREAM complex-mediated quiescence.
  • Greenberg ZJ, Paracatu LC, Monlish DA, [...] Rettig MP, [...] Schuettpelz L
  • Blood 2023
First-in-Humans Evaluation of Safety and Dosimetry of 64Cu-LLP2A for PET Imaging.
  • Laforest R, Ghai A, Fraum TJ, [...] Rettig M, [...] Dehdashti F
  • J Nucl Med 2023
A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity.
  • Kim MY, Jayasinghe R, Devenport JM, [...] Rettig MP, [...] DiPersio JF
  • Nat Commun 2022
Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes.
  • Ferraro F, Miller CA, Christensen KA, [...] Rettig MP, [...] Ley TJ
  • Proc Natl Acad Sci USA 2021
Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome.
  • Smith AM, LaValle TA, Shinawi M, [...] Rettig MP, [...] Ley TJ
  • Nat Commun 2021
Co-evolution of tumor and immune cells during progression of multiple myeloma.
  • Liu R, Gao Q, Foltz SM, [...] Rettig MP, [...] Ding L
  • Nat Commun 2021
Development of [89Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma.
  • Ghai A, Zheleznyak A, Mixdorf M, [...] Rettig M, [...] Achilefu S
  • Eur J Nucl Med Mol Imaging 2021

View All Publications